Ignite Creation Date:
2025-12-24 @ 7:09 PM
Ignite Modification Date:
2025-12-25 @ 4:42 PM
Study NCT ID:
NCT00073957
Status:
COMPLETED
Last Update Posted:
2018-01-23
First Post:
2003-12-10
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sponsor:
Beth Israel Deaconess Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2003-12
Start Date Type:
ACTUAL
Primary Completion Date:
2012-01-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-01-01
Completion Date Type:
ACTUAL
First Submit Date:
2003-12-10
First Submit QC Date:
None
Study First Post Date:
2003-12-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-04-12
Results First Submit QC Date:
None
Results First Post Date:
2018-01-23
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-12-21
Last Update Post Date:
2018-01-23
Last Update Post Date Type:
ACTUAL